Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OurofinoBSP:OFSA3 -2.19%68 OCF Margin % is 54.01% as of Mar. 2026, which is 510% above its 10-year median of 8.86. GuruFocus rates BSP:OFSA3 with a GF Score™ of 68/100 and a GF Value™ of R$26.86 (Fairly Valued). The stock has 2 warning signs investors should review. Among 964 Drug Manufacturers companies, Ourofino ranks better than 62.34% on this metric.
The historical rank and industry rank for Ourofino's OCF Margin % or its related term are showing as below:
BSP:OFSA3'
s OCF Margin % Range Over the Past 10 Years
Min: 5.14 Med: 8.86 Max: 20.17
Current: 13.8
During the past 12 years, the highest OCF Margin % of Ourofino was 20.17%. The lowest was 5.14%. And the median was 8.86%.
BSP:OFSA3's OCF Margin % is ranked better than 62.34% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.04
vs BSP:OFSA3: 13.80
Ourofino OCF Margin % Related Terms
Ourofino OCF Margin % Historical Data
* Premium members only.
The historical data trend for Ourofino's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:OFSA3 vs ZTS, UTHR, VTRS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ourofino OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ourofino's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Ourofino's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ourofino (BSP:OFSA3) has a OCF Margin % of 54.01% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Ourofino and its competitors. This is 510% above median its historical median of 8.86. Over the past decade, Ourofino's OCF Margin % has ranged from 5.14 to 20.17. According to the industry distribution chart, Ourofino ranks #363 out of 964 companies in the Drug Manufacturers industry, placing it in the top 37.7%.
Is Ourofino's OCF Margin % too high?
Ourofino's current OCF Margin % of 54.01% is 510% above median its 10-year median of 8.86. Over the past 10 years, this metric has ranged from a low of 5.14 to a high of 20.17. The Drug Manufacturers industry median OCF Margin % is 10.04. Ourofino's value of 54.01% is 437.9% above this industry median. Based on the distribution chart, Ourofino ranks #363 out of 964 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ourofino has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ourofino ranks #363 out of 964 companies for OCF Margin %. This puts Ourofino in the upper half of its industry. The industry median OCF Margin % is 10.04. Ourofino's value of 54.01% is 437.9% above this benchmark. Historically, Ourofino's own OCF Margin % has ranged from 5.14 to 20.17 over the past decade. While the company's 10-year median is 8.86 vs. the industry median of 10.04, Ourofino has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ourofino's current OCF Margin % of 54.01% is 437.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Ourofino and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ourofino's current OCF Margin % is 54.01%, which is 510% above median its own 10-year median of 8.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$26.86, compared to a current price of R$26.80 — trading 0.2% below its estimated fair value. The current OCF Margin % is 54.01%, which is 510% above median its 10-year median of 8.86 and 437.9% above the Drug Manufacturers industry median of 10.04. Ourofino's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current OCF Margin % is 54.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ourofino (BSP:OFSA3) Overvalued in 2026?
Based on GuruFocus' analysis, Ourofino stock appears to be undervalued.
The current stock price of R$26.80 is trading 0.2% below its estimated GF Value™ of R$26.86.
GuruFocus considers Ourofino to be Fairly Valued.
Key valuation signals for BSP:OFSA3:
OCF Margin %: 54.01% (510% above median its 10-year median of 8.86)
GF Value™: R$26.86 vs. price of R$26.80 (0.2% below fair value)
Industry Position: 437.9% above the Drug Manufacturers median (#363 of 964)
No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
68GF Score
Get the complete analysis for BSP:OFSA3
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:OFSA3 has been successfully added to your 
